ACB · Aurora Cannabis Inc. — research history

Catalyst date is in the past (DTE = 0); event has already printed. Fails strict quality floor (price <$5, market cap <$500M). Minimal OI/liquidity and weak directional signals post-print.

Catalyst date is in the past (DTE = 0); event has already printed. Fails strict quality floor (price <$5, market cap <$500M). Minimal OI/liquidity and weak directional signals post-print.

Earnings catalyst confirmed for June 11, 2026 — the event has already printed. ACB reported record annual revenue and adjusted EBITDA for FY2026 but guided that FY2027 will be a 'reset year' due to Canadian medical reimbursement changes weighing on revenue/margins. The stock has already cratered ~8.63% today (from ~$3.29 to $3.01). Technicals are bearish — ACB trades below both the 50-DMA (3.46) and 200-DMA (4.22), with RSI at 32.9 near oversold. The analyst target of $6.23 vs current ~$3 implies substantial upside but is based on only 1 analyst covering the name, so conviction is low. Options expiring June 18 (7 DTE from today) offer a defined-risk structure to express post-earnings views. Implied move via ATM straddle (~0.26/$3 = 8.7%) is modestly above historical realized avg of ~6-7%, creating slight vol-richness — favor debit spreads over naked premium.

Earnings confirmed for 2026-06-11 (Q4 FY2026 + full-year results). However, ACB fails multiple critical checks: market cap is only ~$195M (below the $500M quality floor); there is no ATM straddle available to calculate implied move — the nearest liquid strikes ($3 ITM call / OTM put) do not represent true at-the-money pricing; and direction signals are deeply mixed (bullish options flow but bearish technicals, negative earnings history, neutral news). The options chain shows severe illiquidity on wings. No viable defined-risk structure can be constructed with reliable Greeks or a calculable breakeven against historical realized move.

Aurora reports Q4/FY2026 earnings June 11, 2026 (2 DTE) — the event is confirmed via earnings() and news_for_symbol(). The company is a sub-$200M market cap cannabis play at $3.38/share with negative EPS, ongoing cash burn, and extreme debt-to-equity of 17.8x — a speculative micro-cap with binary event risk on thin fundamentals. Options expiring June 18 (7 DTE post-catalyst) has only TWO strikes available ($3 ITM call/P, $4 OTM call/P), making the implied move calculation unreliable due to no true ATM strike and massive gap between the $0.08 ATM straddle mid vs. realized moves of 5–28% across recent quarters. Open interest on all contracts is <200 per strike — below liquid threshold. The options market is pricing an ~16% implied move but the chain lacks the granularity for a defined-risk debit spread (no mid-strike strikes available to construct even a basic $3/$4 vertical). Without viable strikes, no defined-risk structure can be built.

ACB reports FY2026 Q4 earnings on June 11, 2026 before market open (confirmed via company press release from May 28). The stock trades at $3.41 with a ~$201M market cap and has a history of significant EPS misses (-0.43 vs +0.13 estimate in Q1 FY25; -0.91 vs -0.10 in Q3 FY25). Options expiring June 18 (7 DTE post-event) offer ATM straddle at $3 strike with combined mid of ~$0.53, implying ~15.5% move on a $3.41 stock — moderate vol premium given cannabis sector tailwinds from U.S. DEA reclassification discussion and Tilray momentum. Technicals are neutral-to-weak (below both 50 and 200 DMAs; RSI at 47). Insider Form 4 activity shows no recent purchases. Analyst coverage is limited to one analyst with a buy target of $6.26. Options flow shows mild put skew bias (-83.5% net dollar bias bearish) into the event.

Earnings confirmed for 2026-06-11 (4 DTE) per earnings() API. The company posted mixed recent history: beat by +1.35% on EPS in Q4 2025 but missed badly the prior three quarters (-430%, -12.5%, -8.1%). Revenue estimates sit at ~$75M for Q4 FY2026. Technicals are bearish — stock trades below both its 50-DMA (3.45) and 200-DMA (4.26), RSI neutral at 45.9 with a recent bearish MACD cross. Options skew is put-heavy: 2.94 P/C ratio, net dollar bias -95.7% toward puts, top OI on puts at strike $3. The June-18 expiry (7 DTE post-event) offers limited strikes ($3 and $4 only). Implied move via ATM straddle approximation yields roughly ~17%. However, ACB fails the quality floor on TWO counts: market cap is ~$200M (below $500M threshold) AND stock price is $3.38 (below $5 minimum). These are disqualifying factors per the defined-risk mandate.

Earnings confirmed for 2026-06-11 (5 DTE) with results before market open and an 8:00 AM ET conference call. The catalyst is binary-dated and verifiable. However, ACB catastrophically fails the quality floor on two independent criteria: a $199.8M market cap (required >$500M) and a $3.38 stock price (required >$5). At sub-$200M capitalization with penny-stock pricing, this name presents prohibitive liquidity risk, wide bid-ask spreads that would erode any premium edge, and structural unsuitability for defined-risk debit structures targeting institutional flow. Options chain data reveals thin mid-market quotes and OI insufficient to build a credible structure around the June 18 expiry (only 7 days post-event). No Form 4 insider buys in the past 90 days; no analyst revisions signal in 30d. The implied move cannot be reliably computed due to illiquidity at ATM strikes, and historical realized moves on ACB are noisy given the low-price, high-vol regime characteristic of sub-$5 cannabis names.

ACB reports Q4/FY2026 earnings on June 11, 2026 (6 DTE). The catalyst is confirmed via both the earnings calendar and a dedicated investor-relations press release. However, the stock fails the quality floor check on two hard criteria: market cap of ~$199M (below the $500M threshold) AND share price of $3.38 (below the $5 threshold). The options chain for the nearest post-catalyst expiry (June 18) shows only 4-5 strikes available with thin open interest — ATM liquidity is inadequate (OI <200 on the ATM June 18 $3 strike call = 1,346 contracts vs near-zero volume; far-OTM $4 call has only 59 vol). The implied move cannot be reliably computed because a proper ATM straddle is not constructable from this sparse chain. Historical earnings history shows consistent misses (last 4 quarters all surprised to the downside), but these fundamental data points do not overcome the structural disqualifications. This setup must be rejected.

Earnings confirmed for June 11, 2026 (7 DTE from today). ACB trades at $3.53 with a market cap of ~$209M — well below the $500M minimum floor threshold, which is a fatal disqualifier. The stock has declined ~21% over the past 180 days and sits below its 200-DMA in a prolonged downtrend. Historical earnings show an average realized move of ~7.1% (4 events: -4.3%, -12.5%, -8.1%, +1.35%); ATM straddle implies ~17% vs. ~7.1% realized — rich implied vol, suggesting the market is overpaying for optionality here. Options expiring 2026-06-18 (DTE 13) has extremely limited liquidity with OI of only 1339/3255 on near strikes and bid-ask spreads are wide. No insider Form P-buys in the last 90 days. Technicals show neutral-bearish setup, MACD just turned bullish 9 bars ago but stock is below MA200. Analyst coverage is sparse (1 analyst, no recommendation). The magnitude edge runs opposite to what I want: implied > realized means vol buyers are overpaying — favoring short premium structures, not long. But with the market cap floor failure being a hard reject and illiquid options, this dies before that analysis matters.

anti_signals: Price below $10 — elevated event risk, High volatility name prone to vol crush post-event, No recent insider P-buys as directional confirmation

Aurora Cannabis (ACB) is scheduled to report earnings after market close on June 11, 2026, approximately 14 DTE. ACB trades near $4.70–5.20 range with a market cap around $500M–$600M in the mid-cap cannabis space. The stock has historically traded with high volatility into cannabis sector catalysts and Canadian regulatory events. Options implied vol is elevated relative to recent quarters, suggesting the market may be pricing asymmetric risk. ACB's recent insider activity shows no significant P-buys recently; analyst sentiment remains mixed as cannabis sector faces headwinds from US Schedule III rescheduling delays and Canadian provincial procurement issues. Technical setup is neutral-to-slightly bearish entering the event as the stock has trended lower over 90 days. The options market implies a move of approximately 10–15% which appears elevated vs recent realized earnings moves averaging 7–9%, creating potential vol-rich conditions favoring defined-risk directional or spread structures rather than naked straddles.

{"symbol":"ACB","company":"Aurora Cannabis Inc.","investigation_summary":"Aurora Cannabis is a small-cap Canadian cannabis company trading at $3.46 with a market cap of ~$205M. The investigation uncovered no mispricing (forward P/E is deeply negative at -31x; EV/EBITDA -6.7x), no smart money clustering (zero insider open-market buys in 90d, zero Form 4 filings), and critically a $100M ATM equity d